StockData

Curis vs Immunome

CRIS and IMNM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRIS and IMNM compare

Immunome is the larger company, worth 2196 times as much as Curis ($2.0B against $911K).

Curis grew revenue faster over the last twelve months (−62.2% versus −63.3% for Immunome).

Curis keeps more of each dollar of sales as profit, with a net margin of −490% compared with −5594% at Immunome.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRISIMNM
Size and price
Market cap$911K$2.0B
Share price$0.436$17.61
Change, 1 year−98.1%6.7%
Change, 5 years−100.0%3.8%
Beta (5Y)0.241.58
Employees24177
StockData Score
Total score77
Valuation score3 (better)0
Growth score00
Performance score01 (better)
Health score46 (better)
Dividend score00
Valuation
P/S0.2× (better)498×
P/B0.2× (better)3.4×
FCF yield–−10.3%
Fair value$6.86–
Margin of safety93.6%–
Growth
Revenue growth (TTM)−62.2% (better)−63.3%
Revenue growth, 5Y average−2.7%–
Profitability
Operating margin−203% (better)−5948%
Net margin−490% (better)−5594%
FCF margin–−5119%
Return on equity–−50.1%
Financial health
Debt / equity0.000.00
Current ratio0.4921.68 (better)
Altman Z-score−96.1836.65 (better)
Piotroski F-score34 (better)
Dividends and buybacks
Buyback yield−2700%–
Shareholder yield−2700%0.00% (better)
Ownership
Held by institutions32.1%104%
Held by insiders20.4%6.4%
Insider net buying, 12 months$5.5K (better)−$25.2M
Short interest, % of float61.8%15.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.